Skip to main content
. 2023 Jan 25;10(8):2206212. doi: 10.1002/advs.202206212

Figure 1.

Figure 1

This study demonstrates an intravenous genetically engineered microparticle loaded with deubiquitin inhibitor, which is a substance derived from lung cancer cells treated with radiation therapy. Microparticles cross the blood‐brain barrier and target and reprogram M2 macrophages at the same time, promoting effector T cell infiltration and the release of pro‐inflammatory cytokines, effectively inhibiting the development of brain metastases of lung cancer.